Neiloufar Family is the Director of Research at Eleusis, with specific oversight over the firm’s development of psychiatric therapeutics. She has overseen the planning, conduct, and analysis of two Phase 1 clinical trials investigating the therapeutic potential of LSD.
CV
Neiloufar Family previously did research on language and cognition as a post-doctoral fellow at the University of Kaiserslautern, and led a study on LSD’s effects on language in collaboration with Imperial College London.
Notable Research Papers
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers (Family, et al., 2020)
- The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial (Yanakieva, Family, et al., 2019)
- Semantic activation in LSD: evidence from picture naming (Family, et al., 2016)
Find more on ResearchGate or PubMed
In our database you will also find her as an author on many more papers.
Media
She has given public talks:
More media:
- Eleusis Announces Phase 1 Trial Results of Lysergic Acid Diethylamide (LSD) in Healthy Older Volunteers, Potential to Evaluate as Disease Modifying Therapy for Alzheimer’s Disease (Business Wire, 2019)
- First study to explore language and LSD since the 1960s: New study shows LSD’s effects on language (ScienceDaily, 2016)
Explore more info with a membership (any level)
🧑 Extended profile information
📈 In-depth psychedelic reports (Sprout & Tree)
🪄 Weekly psychedelic research & implementation newsletter (free)